The European Commission approved AbbVie’s merger with Allergan on the condition the companies sell off Allergan’s late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Allergan already offered to offload the med, which the EU claimed conflicted with AbbVie’s IL-23 candidate risankizumab, along with cystic fibrosis med Zenpep.
In forcing Allergan to give up brazikumab, the EU aims to avoid antitrust concerns in the irritable bowel disease market.
“Our decision makes sure that the merger between AbbVie and Allerganwill not disrupt the development of a promising innovative treatment for these diseases,” said Margrethe Vestager, executive VP of EU Merger Regulation.
Although a final decision from the Federal Trade Commission (FTC) has yet to come, the EU approval gives the first go-ahead to a megamerger expected to create the fourth-largest drugmaker in the world. In September, the FTC sent a “second request” for information on the deal to both drugmakers, giving hope to a coalition of unions and consumer groups that had asked the agency to “carefully examine” the deal and block it outright if necessary.
Full Content: Europa Press
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI